The trade war between the U.S. and China already had American companies rethinking their relationships with manufacturers in China. Then came two additional nails in the coffin. The first was the signing of the United States-Mexico-Canada Agreement (USMCA) into law on Jan. 29, and the second was the outbreak of the coronavirus strain COVID-19. U.S.
Today’s supply chains are challenged by product-line proliferation, shrinking product lifecycles, increased complexity, and massive amounts of data. To add to that list, customers are becoming more demanding and unpredictable; internet-fueled trends are changing on a dime, and promotions and sales are subject to weather, new-product introductions and the economy. To be ready for what
Analyst Insight: Data is important to businesses in formulating strategies, streamlining operations, introducing new products and services, and ensuring customer satisfaction. But data alone isn’t much good unless it’s analyzed, understood and acted upon. Data analysis is benefiting from new technology tools by allowing analysts to dig more deeply into supply chains. At the same
Analyst insight: The pharmaceutical industry is making significant progress in standardizing labels and serialization across supply chains. A group of U.S. pharmaceutical and healthcare providers have shared a snapshot of the industry’s progress in product label standardization — a requirement of the FDA’s 2013 Drug Supply Chain Security Act. By examining product barcodes in wholesalers’
Less than a month into the health crisis that began in China, supply chain disruptions are showing up around the world, from automakers to mobile-phone producers to energy companies. As the human toll from the novel coronavirus continues to rise, with more than 31,000 infected and hundreds dead, the impact on global industry is spreading